IP Library Granted Patent US 12685801
Granted Patent B2
US 12685801 · App. 17/616,434 · Granted Jul 21, 2026

Two-component system for the in situ preparation of an artificial cartilage

Inventors: Thomas Kluge (Wehrheim, DE); Christian Wahnes (Wehrheim, DE); Harro Antheunis (Beek-Ubbergen, NL)
Assignee: Heraeus Medical GmbH
A61L27/26A61L27/52A61L27/54C08L33/08A61L2300/232A61L2300/406A61L2300/802A61L2400/06A61L2430/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12685801
App. No.
17/616,434
Granted
Jul 21, 2026
Kind
B2
Abstract

The invention relates to a two-component system for the in situ preparation of a polymer network by polymerizing acrylate monomers in the presence of a redox initiator couple comprising an activator and an initiator, the system comprising —a first container with a first component, which first component comprises the activator; and —a second container with a second component, which second component comprises the initiator; wherein the activator and/or the initiator is dissolved in an aqueous buffer solution; and wherein one or both containers further comprise —a water soluble acrylic monomer having one acrylate group; and —a water soluble acrylic monomer having two or more acrylate groups; and —at least one glycosaminoglycan; and wherein the combined water content in both containers is at least 50 wt. %, based on the total weight of the contents of both containers.

Claims (52)

1 . A two-component system for the in situ preparation of a polymer network by polymerizing acrylic monomers in the presence of a redox initiator couple comprising an activator and an initiator, the system comprising

a first container that contains a first aqueous buffer solution comprising the activator; and

a second container that contains a second aqueous buffer solution comprising the initiator;

wherein one or both of the first aqueous buffer solution and the second aqueous buffer solution further comprise

a water soluble acrylic monomer having one acrylate group; and

a water soluble acrylic monomer having two or more acrylate groups; and

at least one glycosaminoglycan;

wherein the combined water content in both containers is at least 50 wt. %, based on the total weight of the contents of both containers, and

wherein the acrylic monomer in the first container is completely dissolved in the first aqueous buffer solution and the acrylic monomer in the second container is completely dissolved in the second aqueous buffer solution.

2 . The two-component system according to claim 1 , wherein the contents of the first container and the contents of the second container are completely water-soluble.

3 . The two-component system according to claim 1 , wherein one or both containers further comprise an antibacterial agent selected from an aminoglycoside and glycopeptide.

4 . The two-component system according to claim 1 , wherein the at least one glycosaminoglycan is selected from the group of heparin, heparan sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate and hyaluronic acid.

5 . The two-component system according to claim 1 , comprising acrylic monomer selected from the group of 2-hydroxyethyl methacrylate, acrylamide, 2-carboxyethyl acrylate, 2-(dimethylamino) propyl acrylate, methacrylamide, [2-(acryloyloxy)ethyl]trimethylammonium chloride, N-[Tris(hydroxymethyl)methyl]acrylamide, 3-sulfopropyl acrylate, a salt thereof, 2-(diethylamino)ethyl methacrylate, diacetone acrylamide and N-[3-(dimethylamino)propyl]methacrylamide.

6 . The two-component system according to claim 1 , wherein at least one acrylic monomer having two or more acrylate groups is a poly(1,3-glycerolate) diacrylate or a poly(ethylene glycol) diacrylate.

7 . The two-component system according to claim 1 , comprising a diacrylate having a number average molecular mass (M n ) of 10,000 g/mol or lower, in particular a number average molecular mass (M n ) in the range of 100-1500 g/mol, wherein said number average molecular mass (M n ) is determined by SEC according to DIN 55672-1.

8 . The two-component system according to claim 1 , wherein the activator is selected from the group of N,N-dimethyl-p-toluidine, N,N-bis(2-hydroxyethyl)-p-toluidine, 2-(diethylamino)ethyl methacrylate, 2-(dimethylamino)propyl acrylate, N-[3-(dimethylamino)propyl]methacrylamide and tetramethylethylenediamine.

9 . The two-component system according to claim 1 , wherein the initiator is selected from the group of ammonium persulfate, cumene hydroperoxide and dibenzoyl peroxide.

10 . The two-component system according to claim 1 , wherein the composition of the first container and the second container is chosen in such manner that the entire amount of acrylic monomers is completely dissolved in aqueous buffer solution in the first container or in the second container; and

the polymerization product that forms upon mixing the first aqueous buffer solution and the second aqueous buffer solution exhibits phase separation of the polymerization product and the first and second aqueous buffer solution.

11 . The two-component system according to claim 1 , wherein the pH of the buffer solution in each container is in the range of 7.2 to 7.6.

12 . The two-component system according to claim 1 , wherein the activator comprises a tertiary amino group.

13 . The two-component system according to claim 1 for treatment of a chondral defect or a bone-related disease or condition.

14 . A polymer network comprising

a cross-linked polymer of two or more acrylic monomers comprising a water soluble acrylic monomer having one acrylate group and a water soluble acrylic monomer having two or more acrylate groups;

water that is contained in the cross-linked polymer; and

at least one glycosaminoglycan that is contained in the cross-linked polymer;

wherein the polymer network has a free volume fraction of at least 0.50, wherein the free volume fraction (FVF) is calculated as

FVF=(1 −m d /m g )

wherein m d is the mass of the cross-linked polymer after evaporation of all the water that is contained in it, and m g is the mass of the cross-linked polymer when it is saturated with water, wherein the cross-linked polymer is dissolved in the water to form a hydrogel.

15 . The polymer network according to claim 14 , wherein the cross-linked polymer is permeable for human blood cells.

16 . The polymer network according to claim 14 for treatment of a chondral defect or a bone-related disease or condition.

17 . The two-component system of claim 1 , wherein the first aqueous buffer solution and the second aqueous buffer solution are adapted to react to produce a polymer network having a free volume fraction of at least 0.60.

18 . The two-component system according to claim 1 , wherein the composition of the first container and the second container is chosen in such manner that the entire amount of acrylic monomers is completely dissolved in aqueous buffer solution in the first container or in the second container; and

the polymerization product that forms upon mixing the first aqueous buffer solution and the second aqueous buffer solution is a hydrogel.

19 . The two-component system of claim 1 , wherein:

the contents of the first container consist of the first aqueous buffer solution, which is completely water-soluble; and

the contents of the second container consist of the second aqueous buffer solution, which is completely water-soluble.

20 . The two-component system of claim 1 , wherein the monomer contained in the first container consists of water soluble acrylic monomers, and the monomer contained in the second container consists of water soluble acrylic monomer.

21 . The polymer network of claim 14 , wherein the cross-linked polymer is derived from acrylic monomers consisting of water soluble acrylic monomers having one acrylate group and water soluble acrylic monomers having two or more acrylate groups.

22 . A two-component system for the in situ preparation of a polymer network by polymerizing acrylic monomers in the presence of a redox initiator couple comprising an activator and an initiator, the system comprising

a first container that contains a first aqueous buffer solution comprising the activator; and

a second container that contains a second aqueous buffer solution comprising the initiator;

wherein one or both of the first aqueous buffer solution and the second aqueous buffer solution further comprise

a water soluble acrylic monomer having one acrylate group; and

a water soluble acrylic monomer having two or more acrylate groups; and

at least one glycosaminoglycan;

wherein the combined water content in both containers is at least 50 wt. %, based on the total weight of the contents of both containers, and wherein the total amount of water soluble acrylic monomer is at least 5.0 weight percent of the first and second aqueous buffer solutions.

23 . The two-component system of claim 22 , wherein the total amount of water soluble acrylic monomer is at least 15.0 weight percent of the first and second aqueous buffer solutions.

24 . The two component system of claim 22 , wherein

the water soluble acrylic monomer having one acrylate group has a solubility of at least 20 weight percent; and

the water soluble acrylic monomer having two or more acrylate groups has a solubility of at least 20 weight percent.

25 . The two-component system of claim 22 , adapted for the in situ preparation of a polymer network that is a hydrogel.